Why does immunotherapy fail in some bowel cancer patients? new study aims to find out
NCT ID NCT06353854
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow 600 people with a specific type of advanced colorectal cancer (MSI-high) who are being treated with the immunotherapy drug pembrolizumab. The goal is to understand why about 20-30% of patients do not respond to this treatment. By analyzing tumor samples and patient data, researchers hope to identify markers that predict resistance, helping to personalize treatment decisions in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab
- What this could lead to
- If successful, this could help doctors identify which patients are unlikely to benefit from pembrolizumab, allowing them to choose alternative treatments earlier.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly improve outcomes for participants, and the findings may not lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH - Compiegne
NOT_YET_RECRUITINGCompiègne, France
-
CH - Gustave Dron
NOT_YET_RECRUITINGTourcoing, France
-
CH - Louis Pasteur
NOT_YET_RECRUITINGLe Coudray, France
-
CH Jean Minjoz
NOT_YET_RECRUITINGBesançon, 25030, France
-
CH Saint Joseph
NOT_YET_RECRUITINGMarseille, France
-
CH Saint Joseph - Saint Luc
NOT_YET_RECRUITINGLyon, 69365, France
-
CHR D'Orleans - Hopital de la Source
NOT_YET_RECRUITINGOrléans, 45100, France
-
Caluire et Cuire - Infirmerie Protestante de Lyon
NOT_YET_RECRUITINGLyon, France
-
Centre Hospitalier
NOT_YET_RECRUITINGMulhouse, 68070, France
-
Centre Hospitalier Regional et Universitaire de Lille
RECRUITINGLille, 59037, France
-
Ch - Centre Hospitalier Metropole Savoie
NOT_YET_RECRUITINGChambéry, 73011, France
-
Ch - Centre Hospitalier de Cholet
NOT_YET_RECRUITINGCholet, 49300, France
-
Ch - Centre Hospitalier de La Côte Basque
NOT_YET_RECRUITINGBayonne, 64100, France
-
Ch - Centre Hospitalier de Soisson
NOT_YET_RECRUITINGSoissons, 02209, France
-
Ch - Ch Beauvais
NOT_YET_RECRUITINGBeauvais, France
-
Ch - Chd Vendée
NOT_YET_RECRUITINGLa Roche-sur-Yon, 85925, France
-
Ch - Duchenne
NOT_YET_RECRUITINGBoulogne-sur-Mer, France
-
Ch - Hôpital Saint Joseph
NOT_YET_RECRUITINGMarseille, 13285, France
-
Polyclinique Saint Privat
RECRUITINGBoujan-sur-Libron, 34760, France
-
Prive - Institut Montsouris
RECRUITINGParis, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a vaccine boost immunotherapy against a stubborn cancer?
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Chemo holidays put to the test: can scheduled breaks beat continuous treatment for advanced colorectal cancer?
- Can two immune boosters outsmart Chemo-Resistant colon cancer?
- Could a liver transplant from a living donor help fight colorectal cancer that spread?